Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Stanford Health Care

Optimized preparation pipeline for emergency phage therapy against Pseudomonas aeruginosa at Yale University.

Optimized preparation pipeline for emergency phage therapy against Pseudomonas aeruginosa at Yale University. Scientific reports Würstle, S., Lee, A., Kortright, K. E., Winzig, F., An, W., Stanley, G. L., Rajagopalan, G., Harris, Z., Sun, Y., Hu, B., Blazanin, M., Hajfathalian, M., Bollyky, P. L., Turner, P. E., Koff, J. L., Chan, B. K. 2024; 14 (1): 2657

Abstract

Bacteriophage therapy is one potential strategy to treat antimicrobial resistant or persistent bacterial infections, and the year 2021 marked the centennial of Felix d'Hérelle's first publication on the clinical applications of phages. At the Center for Phage Biology & Therapy at Yale University, a preparatory modular approach has been established to offer safe and potent phages for single-patient investigational new drug applications while recognizing the time constraints imposed by infection(s). This study provides a practical walkthrough of the pipeline with an Autographiviridae phage targeting Pseudomonas aeruginosa (phage vB_PaeA_SB, abbreviated to FSB). Notably, a thorough phage characterization and the evolutionary selection pressure exerted on bacteria by phages, analogous to antibiotics, are incorporated into the pipeline.

View details for DOI 10.1038/s41598-024-52192-3

View details for PubMedID 38302552

View details for PubMedCentralID 2095997